News Releases

Press Releases

  • 8/14/18 7:30 am EDT

    Conference call to be held August 22, 2018 at 4:30 p.m. Eastern time

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and six months ended June 30, 2018 and provided a business update. Management Commentary “I am delighted to report that the second quarter of 2018 was very productive for PAVmed,” said Lishan Aklog., M.D., PAVmed’s Chairman and Chief Executive Officer.  “We added the groundbreaking EsoCheck™ technology to ourmore...
  • 8/9/18 7:30 am EDT
    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report second quarter financial results on or before August 14, 2018 and host a conference call on Wednesday, August 22, 2018 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestonesmore...
  • 7/25/18 7:30 am EDT

    FDA confirms receipt of CarpX 510(k) resubmission for review

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided its most recent update on its business.“Since our last business update less than one month ago, we have experienced a strong surge of investor interest in PAVmed and our products,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “We remain strongly committed to transparency and robust investor communications, and in that spirit, Imore...
  • 7/11/18 7:30 am EDT

    Medical device veteran joins as company approaches important regulatory and commercial milestones

    Immediate focus on building commercialization platforms for CarpX and EsoCheck

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that it has named Shaun M. O’Neil to serve as its first Chief Commercial Officer. Mr. O’Neil will oversee all aspects of the domestic and international commercialization of PAVmed’s products including sales and marketing, clinician engagement and professional education. He will officially assume his role onmore...
  • 7/9/18 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has notified the Company that it has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(1). On June 27, 2018, PAVmed filed a Form 8-K withmore...
  • 6/27/18 8:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided a business update following its recently closed, oversubscribed rights offering. “During our recently completed rights offering we had the pleasure of meeting with many existing investors as well as new investors who were learning about PAVmed for the first time,” said Lishan Aklog, M.D.,more...
  • 6/12/18 4:05 pm EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the closing of its oversubscribed equity subscription rights offering (the “Rights Offering”), which raised the maximum gross proceeds of $10,350,000. Pursuant to the Rights Offering, PAVmed’s stockholders exercised and the Company accepted equity subscription rights resulting in the issuance ofmore...
  • 6/8/18 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced its previously announced equity subscription rights offering (the “Rights Offering”) expired at 5:00 p.m. Eastern Time on Thursday, June 7, 2018 and, as such, the rights are no longer exercisable. The Company received subscriptions that exceeded the number of rights available to be exercised under themore...
  • 6/1/18 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that its board of directors has approved the following changes to its previously announced rights offering: (i) the common stock and Series Z Warrants included in the units will now be tradeable immediately upon their issuance, and (ii) the subscription price shall be $1.15 per unit. Each right now entitles the holdermore...
  • 5/23/18 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, previously announced on May 8, 2018 that the Company had filed a preliminary prospectus as part of a registration statement on Form S-1 with the Securities and Exchange Commission for a rights offering (the “Rights Offering”) to stockholders of record on Monday, May 21, 2018. The Company is now announcing the followingmore...

SEC Filings

Click Here to view PAVmed's SEC filings

INVESTOR PRESENTATION

Click Here to view PAVmed’s current Investor Presentation

PROXY MATERIALS

Click Here to view the Proxy Statement for PAVmed Inc 2018 Annual Meeting

Click Here to view the Annual Report for PAVmed Inc 2018 Annual Meeting